GlaxoSmithKline Integrates Cancer Discovery, Development In “GSK Oncology” Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
The move mirrors actions of other major pharmas, such as Pfizer and Novartis.
You may also be interested in...
GSK’s Witty Looks To Biotech Model In R&D Retool; Mini Labs Will Bid For Project Funding
Planned units include five to 80 scientists, operate within the CEDDs program.
Pfizer Unveils Oncology Business Unit, Gives Failed Compounds Another Try
CHICAGO - With 22 oncology compounds in clinical studies, firm initiates two Phase III studies since Jan. 1; plans to start another five before year-end.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.